

INPLASY202510101

doi: 10.37766/inplasy2025.1.0101

Received: 24 January 2025

Published: 24 January 2025

### Corresponding author:

Francesco Maria Bulletti

francescobull@icloud.com

### Author Affiliation:

1. CHUV Lausanne - DÉPARTEMENT D'HÔPITAL Maternité / Gynécologie et obstétrique. Avenue Pierre Decker 2, 1011 Lausanne (Switzerland).

Bulletti, FM; Guido, M; Palagiano, A; Coccia, ME; Sciorio, R; Evaldo, G; Bulletti, C.

### ADMINISTRATIVE INFORMATION

**Support** - Supported by personal funds.

**Review Stage at time of this submission** - Data analysis.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY202510101

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 24 January 2025 and was last updated on 24 January 2025.

### INTRODUCTION

**Review question / Objective** POF is a risk condition early detectable by clinical evaluation?

**Background** To review the epidemiological data and investigate genetic, immunological, and surgical factors contributing to premature ovarian failure (POF), as well as explore the impact of chemotherapy and ovarian pathologies such as endometriosis and cysts.

**Rationale** Identification of risk factors, genetic predispositions, and clinical implications of POF.

### METHODS

**Strategy of data synthesis** Analyze all the clinical affordable risk factors detection to give the

opportunity to preserve prospective fertility. PubMed, Scopus, and Web of Science were used.

**Eligibility criteria** Epidemiology, genetic mutations, immunological disorders, and surgical outcomes linked to POF.

**Source of evidence screening and selection** Academic research and clinical insights from multidisciplinary contributors. : Identification of risk factors, genetic predispositions, and clinical implications of POF.

**Data management** Review of literature concerning epidemiology, genetic mutations, immunological disorders, and surgical outcomes linked to POF.

**Reporting results / Analysis of the evidence** The prevalence of POF of women under 40. Genetic

---

factors, particularly mutations alongside autoimmune diseases. Chemotherapy is a leading iatrogenic cause, while endometriosis and ovarian cyst surgeries significantly contribute to diminished ovarian reserve.

**Presentation of the results** Tables and figure.

**Language restriction** English.

**Country(ies) involved** Europe - 1. CHUV Lausanne - DÉPARTEMENT D'HÔPITAL Maternité / Gynécologie et obstétrique. Avenue Pierre Decker 2, 1011 Lausanne (Switzerland).

**Other relevant information** The issue have an important social role in protecting that women

**Keywords** Premature ovarian failure, epidemiology, genetic causes, chemotherapy, immunological causes, ovarian surgery.

**Dissemination plans** Scientific paper.

#### **Contributions of each author**

Author 1 - Franbcesco Maria Bulletti - conceptualized and supervised the study.

Email: bulletti@icloud.com

Author 2 - Maurizio Guido - contributed to the epidemiological analysis.

Email: maurizioguido@libero.it

Author 3 - Antonio Palagiano - contributed to data collection and the analysis of immunological causes.

Email: palagiano@gmail.com

Author 4 - Maria Elisabetta Coccia - contributed to data collection and the analysis of immunological causes.

Email: mariaelisabetta.coccia@unifi.it

Author 5 - Romualdo Sciorio - provided insights on surgical and genomic aspects and coordinated the final manuscript preparation.

Email: sciorioromualdo@hotmail.com

Author 6 - Evaldo Giacomucci - contributed to the epidemiological analysis.

Email: evaldo.giacomucci@ausl.bologna.it

Author 7 - Carlo Bulletti - provided insights on surgical and genomic aspects and coordinated the final manuscript preparation.

Email: carlobulletti@gmail.com